न्यूयॉर्क। टेस्टोस्टेरोन की खुराक लेने से ऐसे पुरुषों में दिल के दौरे और स्ट्रोक में काफी कमी आती है, जिनमें हार्मोन का स्तर अस्वाभाविक रूप से कम होता है। एक नए शोध में यह पता चला है।
यूरोपियन एसोसिएशन ऑफ यूरोलॉजी कांग्रेस में प्रस्तुत शोध के निष्कर्ष ने संकेत दिया कि टेस्टोस्टेरोन थेरेपी से पुरुषों के स्वास्थ्य में भी अन्य उपायों से अधिक सुधार देखा गया।
शोध निष्कर्ष के मुताबिक, मरीजों ने अपना वजन कम किया। उनमें नई मांसपेशियों का निर्माण हुआ, उनके कोलेस्ट्रॉल के स्तर और यकृत के कार्य में सुधार हुआ, उनका मधुमेह बेहतर ढंग से नियंत्रित हुआ और उनका रक्तचाप भी कम हो गया।
कहा गया है कि पुरुषों को कुछ मनोवैज्ञानिक और जैविक कार्यो के लिए टेस्टोस्टेरोन की जरूरत होती है। केवल निम्न कोलेस्ट्रॉल स्तर वाले लोग जो अन्य लक्षण प्रदर्शित करते हैं, उनमें टेस्टोस्टेरोन थेरेपी से लाभान्वित होने की संभावना अधिक रहती है।
शोध के निष्कर्ष में कहा गया है, उन लोगों के लिए जो दिल के दौरे और स्ट्रोक के उच्च जोखिम में हैं, जिनमें टेस्टोस्टेरोन की कमी है, यह संभावना है कि हार्मोन को सामान्य स्तर पर वापस लाने से उन्हें अपने समग्र स्वास्थ्य में सुधार के लिए आवश्यक अन्य कदमों के लाभों को अधिकतम करने में मदद मिलती है।
अध्ययन के लिए, टीम ने टेस्टोस्टेरोन की कमी वाले 800 से अधिक पुरुषों को शामिल किया, जिनके पारिवारिक इतिहास, रक्तचाप, कोलेस्ट्रॉल के स्तर, मधुमेह या वजन ने उन्हें दिल के दौरे या स्ट्रोक के उच्च जोखिम में डाल दिया।
केवल सामान्य से नीचे टेस्टोस्टेरोन के स्तर वाले पुरुष, जिन्होंने कम टेस्टोस्टेरोन के लक्षण भी प्रदर्शित किए, जैसे कि खराब मूड, भूख में कमी, अवसाद, स्तंभन दोष, कामेच्छा में कमी या वजन बढ़ना, अनुसंधान में शामिल थे।
आधे से अधिक पुरुषों ने लंबे समय तक टेस्टोस्टेरोन रिप्लेसमेंट थेरेपी का विकल्प चुना, जिससे शोधकर्ताओं ने इस समूह की तुलना उन लोगों से की, जिनकी स्थिति का इलाज नहीं किया गया था।
सभी पुरुषों को अपने हृदय स्वास्थ्य में सुधार के लिए आहार, शराब, धूम्रपान और व्यायाम के मामले में जीवनशैली में बदलाव करने के लिए प्रोत्साहित किया गया।
शोध में कहा गया है कि टेस्टोस्टेरोन थेरेपी पर 412 पुरुषों में से 16 की मौत हो गई और किसी को भी दिल का दौरा या स्ट्रोक नहीं हुआ।
टेस्टोस्टेरोन की खुराक नहीं लेने वाले 393 पुरुषों में से 74 की मृत्यु हो गई, 70 को दिल का दौरा पड़ा और 59 को स्ट्रोक हुआ। (आईएएनएस)
यह भी पढ़े ► ह्दयरोग, कैंसर, स्ट्रोक आदि रोगों में हर्बल दवाएं ज्यादा बेहतर और प्रभावी
New York, Supplementing testosterone significantly reduces heart attacks and strokes in men with unnaturally low levels of the hormone, a new study suggests.
The study, presented at the European Association of Urology Congress, indicated that the health of the men on testosterone therapy also improved by other measures.
They lost weight, had more lean muscle mass, their cholesterol level and liver function improved, their diabetes was better controlled and their blood pressure dropped.
"While men need testosterone for certain psychological and biological functions, only those with low levels who display other symptoms are likely to benefit from testosterone therapy.
"For those at high risk of heart attack and stroke, who are deficient in testosterone, it's likely that bringing the hormone back to normal levels helps them to maximise the benefits of other steps necessary to improve their overall health," the study said.
For the study, the team included over 800 men with testosterone deficiency, whose family history, blood pressure, cholesterol levels, diabetes or weight put them at high risk of heart attack or stroke.
Only men with testosterone levels below normal, who also displayed symptoms of low testosterone, such as low mood, decreased appetite, depression, erectile dysfunction, loss of libido or weight gain, were included in the research.
Just over half of the men opted for long-term testosterone replacement therapy, enabling the researchers to compare this group to those whose condition was left untreated.
All the men were encouraged to make lifestyle changes, in terms of diet, alcohol, smoking and exercise, to improve their cardiovascular health.
Of 412 men on testosterone therapy, 16 died and none suffered a heart attack or stroke, the study said.
Of the 393 men who chose not to take testosterone supplements, 74 died, 70 had a heart attack and 59 suffered a stroke.(IANS)
London, July 7 (IANS) Men with symptomatic Covid-19 and low testosterone are six times more likely to become severely ill and die from the disease, new research has shown.
The study, conducted by researchers at San Raffaele University Hospital in Milan, Italy, found that the lower the levels of testosterone, the higher the likelihood that male patients would need intensive care, be intubated on a ventilator and remain in hospital over a longer period.
For the study, the team compared 286 male Covid patients, who came to the emergency department, with 305 healthy male volunteers between February and May 2020.
Nearly 90 per cent of the patients had testosterone below 9.2 nanomoles per litre (nmol/l), compared to just 17 per cent of the healthy volunteers. Those with testosterone levels between 3-4 nmol/l and had mild symptoms or were admitted to hospital, while those admitted to ICU or died of the disease had just 0.7-1.0 nmol/l.
"At the start of the Covid pandemic, we were seeing far more men than women coming to hospital and suffering very severe forms of the disease. We immediately thought this might be related to male hormone levels, particularly testosterone," Professor Andrea Salonia, a specialist in urology and endocrinology at the hospital.
"But we never expected to see such a high proportion of Covid patients with these extremely low levels of testosterone, in comparison to a similar group of healthy men. The relationship is very clear: the lower the testosterone, the higher the severity of the condition and likelihood of death. I've never seen anything like it in my 25 years in the field," Salonia added.
However, since the team does not have data on the testosterone levels in the patients before they contracted Covid-19, they cannot say whether low testosterone was a pre-existing long-term condition that exacerbated the disease or whether it was caused by the SARS-COV2 virus.
"Testosterone does play a role in protecting men from disease. However, it's also possible that the virus itself is able to induce an acute reduction in testosterone levels, which then predisposes these men to a worse outcome," Salonia said.
The findings will be presented at the 2021 European Association of Urology congress (EAU21), which starts from July 8-12.
Read More ► Higher testosterone levels ups diabetes risk in women
Dysfunction of glucose metabolism resulting in hyperglycemia, a high blood sugar level, has been found in 14.4 percent of patients who survived coronavirus, according to a global study published in the Diabetes, Obesity and Metabolism Journal.
With India's total caseload rose to 3,02,33,183 and achieving the third-highest vaccination number, after China and the US, the challenge for health authorities now is to counter the onset of diabetes in post-Covid patients.
They say the fight against hyperglycemia can be countered with ayurvedic formulations like CSIR-developed BGR-34.
The formulation is based on natural bioactive compounds with Dipeptidyl-peptidase-4 (DPP-4) inhibitory effects to manage blood glucose levels.
Quoting a recent study in the Elsevier journal, they said it has shown DPP-4 inhibitors to be most safe to tackle post-Covid hyperglycemia.
The researchers who conducted the study said every patient admitted to a Covid care facility should be investigated for hyperglycemia on the day of admission itself.
What is BGR-34 all about?
BGR-34 is an ayurvedic-derived product for the management of diabetes. It includes natural bioactive compounds of the herbal plant Daruharidra with a DPP-4 inhibitory effect.
It has been developed by two labs of the Council of Scientific and Industrial Research (CSIR) -- the National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP).
Post-Covid hyperglycemia has symptoms like abdominal pain, nausea and vomiting, and shortness of breath.
The condition is caused by the virus by damaging pancreatic beta cells leading to insufficient insulin production in the body. The increasing number of this condition among post-Covid patients is not good for India, home to one in six people with diabetes in the world.
According to research published in the Journal of Drug Research, the primary source of DPP-4 inhibitors is the herbal plant Daruharidra.
A.K.S. Rawat, a scientist with the Lucknow-based NBRI, which developed BGR-34, said a key ingredient of the ayurvedic formulation is Daruharidra.
Besides Daruharidra, BGR-34 has other herbal elements also that can keep hyperglycemia in check. Gymnemic acid sourced from Gudmaar medicinal plant and Trigonoside IB found in fenugreek that controls hyperglycemia are present in BGR-34, AIMIL Pharmaceuticals executive director Sanchit Sharma told IANS.
The company produces the CSIR-developed BGR-34 ayurvedic formulation.
Giloy, Vijaysaar, and Majeeth, all known for their anti-diabetic properties, are also present in BGR-34, said Rawat.
He said the power of Ayurveda has once again been established by several studies that indicate the efficacy of bioactive compounds produced by plants in the treatment of post-Covid new-onset diabetes.
Read More► AIMIL BGR-34 Tablet: Benefits, Side Effects, Composition, Dosage & Price
Hong Kong, June 20 (IANS) People who got Pfizer's Covid-19 vaccine showed "substantially higher" levels of antibodies compared to those who received China's Sinovac shots, according to a new study.
The study, led by University of Hong Kong (HKU), aims to estimate the incidence of natural infections over time and level of population immunity due to infections and vaccinations, the South China Morning Post reported on Saturday.
The presence of antibodies is a sign that the vaccine is working to protect an individual, although the quantity of the proteins generated by the body's immune system to identify and neutralise the coronavirus does not directly correlate to the level of immunity, the report said.
Some who received the Sinovac vaccine might need a third booster shot as well, lead researcher Professor Benjamin Cowling, an epidemiologist with HKU was quoted as saying by the TRTWorld.
The study involved tracking the antibody responses of 1,000 people who received either vaccine.
On June 1, the World Health Organization (WHO) authorised the Sinovac-CoronaVac Covid-19 vaccine for emergency use.
The two-dose Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings.
Based on available evidence, the WHO recommended the vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks.
Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51 per cent of those vaccinated and prevented severe Covid-19 and hospitalisation in 100 per cent of the studied population.
On the other hand, the Pfizer-BioNTech Covid vaccine is based on mRNA technology and has been authorised for emergency use by the US Food and Drug Administration.
Studies have shown that the two-dose shot is effective against Covid-19, as well as its variants - Delta, Gamma and Beta.
Toronto, June 3 (IANS) SARS-CoV-2, the virus causing Covid-19, infects immature red blood cells (RBC), reducing oxygen in the blood and impairing the immune response, say researchers.The study, published in the journal Stem Cell Reports, sheds light on why many Covid-19 patients, even those not in hospital, are suffering from hypoxia -- a potentially dangerous condition in which there is decreased oxygenation in the body's tissues. The study also shows why anti-inflammatory drug dexamethasone has been an effective treatment for those with the virus."Low blood-oxygen levels have been a significant problem in Covid-19 patients," said study lead Shokrollah Elahi, Associate Professor in the Faculty of Medicine and Dentistry at University of Alberta, Canada."Because of that, we thought one potential mechanism might be that Covid-19 impacts red blood cell production," Elahi added.Elahi's team was the first in the world to demonstrate that immature RBCs expressed the receptor ACE2 and a co-receptor, TMPRSS2, which allowed SARS-CoV-2 to infect them.For the study, the team examined the blood of 128 patients with Covid-19. The patients included those who were critically ill and admitted to the ICU, those who had moderate symptoms and were admitted to hospital, and those who had a mild version of the disease and only spent a few hours in hospital.The researchers found that, as the disease became more severe, more immature RBCs flooded into blood circulation, sometimes making up as much as 60 per cent of the total cells in the blood. By comparison, immature RBCs make up less than one per cent, or none at all, in a healthy individual's blood.Further, the team also found the dexamethasone drug suppresses the response of the ACE2 and TMPRSS2 receptors to SARS-CoV-2 in immature RBCs, reducing the opportunities for infection. The drug also increases the rate at which the immature RBCs mature, helping the cells shed their nuclei faster. Without the nuclei, the virus has nowhere to replicate, the researchers said.--IANSrvt/vd